阿帕替尼用于二线及以上治疗失败的晚期大肠癌患者中的临床效果  

Clinical effect of apatinib in patients with advanced colorectal cancer who failed to receive second-line or more treatment

作　　者：朱宏财 岳丽娟[1] 张晶晶[1] 薛玲[1] 侯新丽[1] ZHU Hongcai;YUE Lijuan;ZHANG Jingjing;XUE Ling;HOU Xinli(Hanzhong Central Hospital,Hanzhong 723000,China)

机构地区：[1]汉中市中心医院,陕西汉中723000

出　　处：《临床医学研究与实践》2021年第31期67-69,共3页Clinical Research and Practice

基　　金：汉中市中心医院院级科研基金(No.YK1823)。

摘　　要：目的分析阿帕替尼用于二线及以上治疗失败的晚期大肠癌患者中的临床效果。方法选取2016年1月至2020年6月我院收治的56例二线及以上治疗失败的晚期大肠癌患者,按治疗方案的不同将其分为对照组(常规化疗)和观察组(常规化疗联合阿帕替尼治疗),各28例。比较两组的近期疗效、半年生存率、肿瘤标志物及血管新生成指标水平、毒副反应发生情况。结果观察组的疾病控制率、半年生存率均高于对照组(P<0.05)。治疗后,观察组HSP60、CA199、CA242、HIF-1α、VEGF水平均低于对照组(P<0.05)。观察组的毒副反应总发生率略高于对照组,但组间比较,差异不显著(P>0.05)。结论阿帕替尼用于二线及以上治疗失败的晚期大肠癌中,可提高近期疗效,有效控制肿瘤标志物及血管新生成指标水平,不良反应相对较轻且可控制,安全性较好。Objective To analyze the clinical effect of apatinib in patients with advanced colorectal cancer who failed to receive second-line or more treatment.Methods From January 2016 to June 2020,56 patients with advanced colorectal cancer who failed to receive second-line or more treatment admitted in our hospital were selected.According to the different treatment regimen,the patients were divided into control group(conventional chemotherapy)and observation group(conventional chemotherapy combined with apatinibtreatment),with 28 cases in each group.The short-term efficacy,half-year survival rate,tumor markers and angiogenesis indexes levels,and the occurrence of toxic and side effects were compared between the two groups.Results The disease control rate and half-year survival rate in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of HSP60,CA199,CA242,HIF-1αand VEGF in the observation group were lower than those in the control group(P<0.05).The total incidence of toxic and side effects in the observation group was slightly higher than that in the control group,but there was no significant difference between the two groups(P>0.05).Conclusion Apatinib applied in patients with advanced colorectal cancer who failed to receive second-line or more treatment can improve the short-term efficacy,effectively control the levels of tumor markers and angiogenesis indexes,and has relatively mild,controllable adverse reactionsand good safety.

关 键 词：晚期大肠癌 阿帕替尼 肿瘤标志物 血管新生 毒副反应 

分 类 号：R735.34[医药卫生—肿瘤]